Grazia Sanpaolo

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Esther Natalie Olíva, Caterina Alati, Valeria Santini et al. · The Lancet Haematology · 2017 · 159 citations · Full text

Eltrombopag Versus Placebo, Thrombosis, Thrombopoiesis +7

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

Giovanni D’Arena, Paolo G. Gobbi, Chiara Broglia et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 99 citations · Full text

Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes

Pellegrino Musto, Francesco Lanza, Enrico Balleari et al. · British Journal of Haematology · 2004 · 97 citations · Full text

Hematological Malignancy, Thrombosis, Bone Marrow Failure +12

Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (<scp>GIMEMA MDS</scp>0306 <scp>T</scp>rial)

Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci et al. · European Journal Of Haematology · 2014 · 95 citations · Full text

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

Fabio Efficace, Gianluca Gaïdano, Massimo Breccia et al. · The Lancet Oncology · 2015 · 84 citations

Hematological Malignancy, Prognostic Evaluation, Fatigue Management +7